AZN – AstraZeneca PLC
AstraZeneca PLCAZN
$193.10Name : AstraZeneca PLC
Sector : Healthcare
Industry: Drug Manufacturers - General
Mark. Cap: $299,351,998,464.00
EPSttm : 6.54
AstraZeneca PLC
$193.10
2.48%$4.68
AZN — Price & Forward EBITDA
Forward EBITDA (M)
Float Short %
0.13
Margin Of Safety %
7
Put/Call OI Ratio
1.01
EPS Next Q Diff
0.22
EPS Last/This Y
-1.42
EPS This/Next Y
0.79
Price
188.43
Target Price
221.86
Analyst Recom
1.61
Performance Q
1.08
Upside
-23.5%
Beta
0.43
Ticker: AZN
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2026-03-02 | AZN | 203.73 | 0.97 | 0.49 | 85689 |
| 2026-03-03 | AZN | 201.78 | 0.97 | 1.18 | 85743 |
| 2026-03-04 | AZN | 201.65 | 0.97 | 0.83 | 85673 |
| 2026-03-05 | AZN | 197.66 | 0.97 | 0.65 | 85533 |
| 2026-03-06 | AZN | 194.37 | 0.97 | 0.39 | 85389 |
| 2026-03-09 | AZN | 195 | 0.97 | 0.38 | 85405 |
| 2026-03-10 | AZN | 194.91 | 0.97 | 1.39 | 85513 |
| 2026-03-11 | AZN | 193.29 | 0.97 | 0.84 | 85665 |
| 2026-03-12 | AZN | 192.54 | 0.97 | 0.57 | 85631 |
| 2026-03-13 | AZN | 192.5 | 0.97 | 0.60 | 85631 |
| 2026-03-17 | AZN | 191.32 | 0.96 | 0.81 | 86005 |
| 2026-03-18 | AZN | 188.42 | 0.96 | 0.03 | 86063 |
| 2026-03-19 | AZN | 188.9 | 0.96 | 0.16 | 86868 |
| 2026-03-20 | AZN | 183.54 | 0.96 | 1.31 | 87066 |
| 2026-03-23 | AZN | 184.09 | 1.08 | 0.43 | 77962 |
| 2026-03-24 | AZN | 185.77 | 1.07 | 0.24 | 78959 |
| 2026-03-25 | AZN | 187.16 | 1.06 | 0.21 | 79111 |
| 2026-03-26 | AZN | 183.37 | 1.02 | 0.52 | 81448 |
| 2026-03-27 | AZN | 188.43 | 1.01 | 2.24 | 82900 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2026-03-02 | AZN | 203.73 | - | 3952.8 | 5.23 |
| 2026-03-03 | AZN | 201.66 | - | 4206.7 | 5.23 |
| 2026-03-04 | AZN | 201.59 | - | 4558.3 | 5.23 |
| 2026-03-05 | AZN | 197.63 | - | 4117.5 | 6.87 |
| 2026-03-06 | AZN | 194.51 | - | 4177.8 | 6.87 |
| 2026-03-09 | AZN | 194.87 | - | 5375.8 | 6.87 |
| 2026-03-10 | AZN | 195.07 | - | 5115.5 | 6.87 |
| 2026-03-11 | AZN | 193.27 | - | 4537.2 | 6.87 |
| 2026-03-12 | AZN | 192.23 | - | 4854.0 | 6.87 |
| 2026-03-13 | AZN | 189.96 | - | 4840.4 | 6.87 |
| 2026-03-17 | AZN | 191.30 | - | 4839.7 | 5.18 |
| 2026-03-18 | AZN | 188.36 | - | 4491.6 | 5.18 |
| 2026-03-19 | AZN | 188.88 | - | 4633.9 | 5.18 |
| 2026-03-20 | AZN | 183.60 | - | 4461.0 | 5.18 |
| 2026-03-23 | AZN | 184.06 | - | 4566.6 | 5.18 |
| 2026-03-24 | AZN | 185.77 | - | 5424.2 | 5.18 |
| 2026-03-25 | AZN | 187.15 | - | 5345.3 | 5.18 |
| 2026-03-26 | AZN | 183.29 | - | 4663.3 | 5.18 |
| 2026-03-27 | AZN | 188.43 | - | 5549.9 | 5.18 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2026-03-02 | AZN | 0.00 | -38.83 | 0.17 |
| 2026-03-03 | AZN | 0.00 | -38.83 | 0.17 |
| 2026-03-04 | AZN | 0.00 | -38.83 | 0.17 |
| 2026-03-05 | AZN | 0.00 | -38.83 | 0.17 |
| 2026-03-06 | AZN | 0.00 | -38.83 | 0.17 |
| 2026-03-09 | AZN | 0.00 | -21.65 | 0.17 |
| 2026-03-10 | AZN | 0.00 | -21.65 | 0.17 |
| 2026-03-11 | AZN | 0.00 | -21.65 | 0.16 |
| 2026-03-12 | AZN | 0.00 | -21.65 | 0.16 |
| 2026-03-13 | AZN | 0.00 | -21.65 | 0.16 |
| 2026-03-17 | AZN | 0.00 | -13.25 | 0.16 |
| 2026-03-18 | AZN | 0.00 | -13.25 | 0.16 |
| 2026-03-19 | AZN | 0.00 | -13.25 | 0.16 |
| 2026-03-20 | AZN | 0.00 | -13.25 | 0.16 |
| 2026-03-23 | AZN | 0.00 | -13.03 | 0.16 |
| 2026-03-24 | AZN | 0.00 | -13.03 | 0.16 |
| 2026-03-25 | AZN | 0.00 | -13.03 | 0.13 |
| 2026-03-26 | AZN | 0.00 | -13.03 | 0.13 |
| 2026-03-27 | AZN | 0.00 | -13.03 | 0.13 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
1.06
Avg. EPS Est. Current Quarter
1.23
Avg. EPS Est. Next Quarter
1.28
Insider Transactions
Institutional Transactions
-13.03
Beta
0.43
Average Sales Estimate Current Quarter
14719
Average Sales Estimate Next Quarter
15320
Fair Value
201.74
Quality Score
95
Growth Score
97
Sentiment Score
74
Actual DrawDown %
11.4
Max Drawdown 5-Year %
-28.7
Target Price
221.86
P/E
28.76
Forward P/E
16.21
PEG
1.33
P/S
4.97
P/B
6
P/Free Cash Flow
24.03
EPS
6.55
Average EPS Est. Cur. Y
5.18
EPS Next Y. (Est.)
5.97
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
17.41
Relative Volume
2.02
Return on Equity vs Sector %
-6.3
Return on Equity vs Industry %
-15.7
EPS 1 7Days Diff
EPS 1 30Days Diff
0.05
EBIT Estimation
5549.9
◆
AZN
Healthcare
$188.42
Swing / Pullback
Buy the dip on strong trends
WEAK
RSI
45.1
Range 1M
30.1%
Sup Dist
3.5%
Momentum Growth
Ride accelerating trends
WEAK
EPS Yr
12.5%
EPS NY
12.8%
52W%
74.4%
Long-Term Value
Quality companies, undervalued
WEAK
🔴 SELL
-9.5% upside
Upside
-9.5%
Quality
95
MoS
7%
AstraZeneca PLCSector: Healthcare
Industry: Drug Manufacturers - General
Employees: 96100
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Crestor, Andexxa, Onglyza, Symlin, XIGDUO XR, Atacand, Atacand HCT, Atacand Plus, Farxiga/Forxiga, Plendil, Modip, Splendil, Munobal, Flodil, Tenormin, Tenormine, Prenormine, Atenol, Zestril, Brilinta/Brilique, Komboglyze, Qtern, Wainua, Byetta, Lokelma, Seloken ZOK, Toprol-XL, Betaloc ZOK, XIGDUO, Accolate, Accoleit, Vanticon, Bricanyl Respules, Eklira Genuair/Tudorza/Bretaris, Pulmicort Turbuhaler, Symbicort Turbuhaler, Airsupra, Bricanyl Turbuhaler, Fasenra, Rhinocort, Tezspire, Bevespi Aerosphere, Daliresp/Daxas, Oxis Turbuhaler, Saphnelo, Breztri Aerosphere, Duaklir Genuair, Pulmicort Respules, and Symbicort pMDI. It also provides Beyfortus, Kavigale, Evusheld, Fluenz/FluMist, Synagis, Kanuma, Ultomiris, Koselugo, Voydeya, Soliris, Strensiq, Nexium, and other medicines. The company offers its products for ocology, cardiovascular, renal and metabolism, respiratory & immunology, vaccines and immune, and therapies rare diseases. It serves primary and specialty care physicians through distributors and local representative offices in the United Kingdom, the Americas, rest of Europe, Asia, Africa, and Australasia. It has a strategic agreement with Tempus and Pathos to develop the largest multimodal foundation model in oncology; and a strategic research collaboration with CSPC Pharmaceutical Group Limited to advance the discovery and development of novel oral candidates, with the potential to treat diseases across multiple indications. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
AZN
Latest News
—
Caricamento notizie per AZN…
stock quote shares AZN – AstraZeneca PLC Stock Price stock today
news today AZN – AstraZeneca PLC stock forecast ,stock prediction 2023 2024 2025
marketwatch AZN – AstraZeneca PLC yahoo finance google finance
stock history AZN – AstraZeneca PLC invest stock market
stock prices AZN premarket after hours
ticker AZN fair value insiders trading